Global Addictions Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB504245410

Publication Date:

May 5, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Addiction is a brain disorder characterized by compulsive engagement in rewarding stimuli despite adverse consequences.Despite the involvement of a number of psychosocial factors, a biological process 鈥� one which is induced by repeated exposure to an addictive stimulus 鈥� is the core pathology that drives the development and maintenance of an addiction.
Highlights
The global Addictions Therapeutics market was valued at US$ 4975.1 million in 2022 and is anticipated to reach US$ 6401.2 million by 2029, witnessing a CAGR of 4.3% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
With the rising alcohol, opioid, and tobacco addiction across the world, many public, private, and government organizations are conducting programs to increase awareness about substance abuse and its health implications. For instance, the Substance Abuse and Mental Health Services Administration (SAMHSA) in the US sponsors the Recovery Month to increase awareness about mental and substance use disorders and celebrate recovery. The organization also offers services to people with substance use disorders. Also, in countries such as India, government bodies provide financial assistance to many NGOs and urban local agencies to carry out combines services to spread awareness and rehabilitate individuals with addiction disorders.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Addictions Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Addictions Therapeutics.
The Addictions Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Addictions Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Addictions Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Alkermes Plc
Amneal Pharmaceuticals Inc.
Indivior Plc
Johnson & Johnson Services Inc.
Mylan NV
Novartis AG
Novo Nordisk AS
Opiant Pharmaceuticals Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Segment by Type
Alcohol Addiction Therapeutics
Tobacco Addiction Therapeutics
Drug Addiction Therapeutics
Segment by Application
Public
Private
Government
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Addictions Therapeutics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Addictions Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Alcohol Addiction Therapeutics
1.2.3 Tobacco Addiction Therapeutics
1.2.4 Drug Addiction Therapeutics
1.3 麻豆原创 by Application
1.3.1 Global Addictions Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Public
1.3.3 Private
1.3.4 Government
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Addictions Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Addictions Therapeutics Growth Trends by Region
2.2.1 Global Addictions Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Addictions Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Addictions Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Addictions Therapeutics 麻豆原创 Dynamics
2.3.1 Addictions Therapeutics Industry Trends
2.3.2 Addictions Therapeutics 麻豆原创 Drivers
2.3.3 Addictions Therapeutics 麻豆原创 Challenges
2.3.4 Addictions Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Addictions Therapeutics Players by Revenue
3.1.1 Global Top Addictions Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Addictions Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Addictions Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Addictions Therapeutics Revenue
3.4 Global Addictions Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Addictions Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Addictions Therapeutics Revenue in 2022
3.5 Addictions Therapeutics Key Players Head office and Area Served
3.6 Key Players Addictions Therapeutics Product Solution and Service
3.7 Date of Enter into Addictions Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Addictions Therapeutics Breakdown Data by Type
4.1 Global Addictions Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Addictions Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Addictions Therapeutics Breakdown Data by Application
5.1 Global Addictions Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Addictions Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Addictions Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America Addictions Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Addictions Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America Addictions Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Addictions Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe Addictions Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Addictions Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Addictions Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Addictions Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Addictions Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Addictions Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Addictions Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Addictions Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America Addictions Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Addictions Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Addictions Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Addictions Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Addictions Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Addictions Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Addictions Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alkermes Plc
11.1.1 Alkermes Plc Company Detail
11.1.2 Alkermes Plc Business Overview
11.1.3 Alkermes Plc Addictions Therapeutics Introduction
11.1.4 Alkermes Plc Revenue in Addictions Therapeutics Business (2018-2023)
11.1.5 Alkermes Plc Recent Development
11.2 Amneal Pharmaceuticals Inc.
11.2.1 Amneal Pharmaceuticals Inc. Company Detail
11.2.2 Amneal Pharmaceuticals Inc. Business Overview
11.2.3 Amneal Pharmaceuticals Inc. Addictions Therapeutics Introduction
11.2.4 Amneal Pharmaceuticals Inc. Revenue in Addictions Therapeutics Business (2018-2023)
11.2.5 Amneal Pharmaceuticals Inc. Recent Development
11.3 Indivior Plc
11.3.1 Indivior Plc Company Detail
11.3.2 Indivior Plc Business Overview
11.3.3 Indivior Plc Addictions Therapeutics Introduction
11.3.4 Indivior Plc Revenue in Addictions Therapeutics Business (2018-2023)
11.3.5 Indivior Plc Recent Development
11.4 Johnson & Johnson Services Inc.
11.4.1 Johnson & Johnson Services Inc. Company Detail
11.4.2 Johnson & Johnson Services Inc. Business Overview
11.4.3 Johnson & Johnson Services Inc. Addictions Therapeutics Introduction
11.4.4 Johnson & Johnson Services Inc. Revenue in Addictions Therapeutics Business (2018-2023)
11.4.5 Johnson & Johnson Services Inc. Recent Development
11.5 Mylan NV
11.5.1 Mylan NV Company Detail
11.5.2 Mylan NV Business Overview
11.5.3 Mylan NV Addictions Therapeutics Introduction
11.5.4 Mylan NV Revenue in Addictions Therapeutics Business (2018-2023)
11.5.5 Mylan NV Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Detail
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Addictions Therapeutics Introduction
11.6.4 Novartis AG Revenue in Addictions Therapeutics Business (2018-2023)
11.6.5 Novartis AG Recent Development
11.7 Novo Nordisk AS
11.7.1 Novo Nordisk AS Company Detail
11.7.2 Novo Nordisk AS Business Overview
11.7.3 Novo Nordisk AS Addictions Therapeutics Introduction
11.7.4 Novo Nordisk AS Revenue in Addictions Therapeutics Business (2018-2023)
11.7.5 Novo Nordisk AS Recent Development
11.8 Opiant Pharmaceuticals Inc.
11.8.1 Opiant Pharmaceuticals Inc. Company Detail
11.8.2 Opiant Pharmaceuticals Inc. Business Overview
11.8.3 Opiant Pharmaceuticals Inc. Addictions Therapeutics Introduction
11.8.4 Opiant Pharmaceuticals Inc. Revenue in Addictions Therapeutics Business (2018-2023)
11.8.5 Opiant Pharmaceuticals Inc. Recent Development
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Detail
11.9.2 Pfizer Inc. Business Overview
11.9.3 Pfizer Inc. Addictions Therapeutics Introduction
11.9.4 Pfizer Inc. Revenue in Addictions Therapeutics Business (2018-2023)
11.9.5 Pfizer Inc. Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Addictions Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Addictions Therapeutics Business (2018-2023)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Alkermes Plc
Amneal Pharmaceuticals Inc.
Indivior Plc
Johnson & Johnson Services Inc.
Mylan NV
Novartis AG
Novo Nordisk AS
Opiant Pharmaceuticals Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.